Johnson & Johnson Avoids Trial in Tracleer Antitrust Case, Pays $65M to End Generic Block Allegations

The event is a clear, low-cost resolution of a high-risk legal claim. On March 13, 2026, a federal court in Maryland granted preliminary approval for a $65 million settlement in an antitrust class action lawsuit. This came just weeks before a scheduled 25-day jury trial was set to begin. The defendants are Johnson & Johnson's Janssen unit and Actelion Pharmaceuticals, with the parent company's liability stemming from its 2017 acquisition of Actelion.

The core allegation is straightforward: Actelion blocked generic manufacturers from obtaining samples of its drug Tracleer, a move that delayed generic entry for over three years after the patent expired. Plaintiffs, including the Government Employees Health Association, claimed this scheme forced payors to pay higher prices, resulting in overpayments of more than $100 million. The settlement covers Tracleer purchases in 31 states and the District of Columbia between December 2015 and September 2024.

The key tactical takeaway is that Johnson & Johnson avoided a jury trial and the significant uncertainty that comes with it. The company agreed to pay $65 million without admitting wrongdoing, a sum that represents a meaningful but not crippling recovery for the plaintiffs. This resolution removes a potential overhang from the financial statements for the Tracleer franchise.

The Antitrust Mechanics & Financial Impact

The settlement resolves a specific and well-documented scheme. Actelion, the drug's manufacturer, allegedly blocked generic competition by contractually forbidding its distributors from selling samples of Tracleer to would-be generic makers. This was a critical move because the FDA requires samples for bioequivalence testing, a mandatory step before any generic can be approved. By cutting off this path, Actelion delayed generic entry for over three years after the original patent expired.

The financial magnitude of the settlement is telling. The $65 million payout is a small fraction of the hundreds of millions of dollars in overpayments alleged to have occurred during that delay. This stark contrast underscores the settlement's role as a low-cost exit from a high-risk legal claim. The company avoided the potential for a much larger judgment, which could have been based on the scale of the alleged harm.

Tracleer's blockbuster status is key to understanding the stakes. The drug treats pulmonary arterial hypertension, a serious condition, and was reportedly a major profit driver for Actelion, generating billions in annual revenue before its patent expired in December 2015. The alleged scheme was designed to protect that lucrative monopoly.

Looking ahead, the patent landscape suggests the immediate competitive threat remains low. While the original patent expired years ago, new patent protections are still in place. The next patent expiry is estimated for December 2027, meaning a generic launch is not imminent. This provides a buffer for the branded drug's revenue stream, though it also means the company may face similar legal challenges in the future if generic development is again impeded.

The Path to Resolution & What's Next

The immediate next step is a judge's final approval. The settlement was filed in federal court in Maryland on March 5, 2026, and received preliminary approval last week. However, the deal is not yet final. It is now pending review by the presiding judge, who has the authority to either grant final approval or reject it. If the judge finds the terms inadequate, the settlement could be contested, potentially leading to a trial or forcing the parties to negotiate a revised agreement.

The primary risk now is reputational and regulatory. This case is part of a broader, aggressive trend of antitrust actions targeting drugmakers for delaying generic competition. The precedent set by this settlement-where a major pharmaceutical company pays tens of millions to resolve allegations of blocking generic entry-could embolden plaintiffs' attorneys and regulators. It signals that such tactics are not just a business risk but a legal one, potentially opening the door for similar lawsuits against other drugs in Johnson & Johnson's portfolio.

Looking forward, investors should monitor for any new class action filings or regulatory scrutiny related to other drugs. The mechanics of the Tracleer case-blocking sample access to delay generics-are a known playbook. With Johnson & Johnson's vast pipeline and portfolio, the company must now manage the heightened risk that this legal precedent will be applied to other products, creating a potential overhang for future earnings and increasing the cost of defending against such claims.